CY1123409T1 - Αντισωματα κατα toy icos (επαγωγιμος συνδιεγερτης τ-κυτταρων) - Google Patents

Αντισωματα κατα toy icos (επαγωγιμος συνδιεγερτης τ-κυτταρων)

Info

Publication number
CY1123409T1
CY1123409T1 CY20201100755T CY201100755T CY1123409T1 CY 1123409 T1 CY1123409 T1 CY 1123409T1 CY 20201100755 T CY20201100755 T CY 20201100755T CY 201100755 T CY201100755 T CY 201100755T CY 1123409 T1 CY1123409 T1 CY 1123409T1
Authority
CY
Cyprus
Prior art keywords
stimulator
inducible
cell
antibodies against
against icos
Prior art date
Application number
CY20201100755T
Other languages
English (en)
Inventor
Stephen Sazinsky
Jennifer S. MICHAELSON
Sriram Sathyanarayanan
Kutlu Goksu ELPEK
Original Assignee
Jounce Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jounce Therapeutics, Inc. filed Critical Jounce Therapeutics, Inc.
Publication of CY1123409T1 publication Critical patent/CY1123409T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Στο παρόν παρέχονται, διάφορες υλοποιήσεις σχετικές με αντισώματα. Μερικές από τις υλοποιήσεις περιλαμβάνουν αντισώματα-αγωνιστές που δεσμεύουν τον ICOS. Τέτοια αντισώματα μπορούν να χρησιμοποιηθούν σε μεθόδους θεραπείας του καρκίνου, για παράδειγμα.
CY20201100755T 2015-03-23 2020-08-12 Αντισωματα κατα toy icos (επαγωγιμος συνδιεγερτης τ-κυτταρων) CY1123409T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562137034P 2015-03-23 2015-03-23
US201562147484P 2015-04-14 2015-04-14
US201562156588P 2015-05-04 2015-05-04
US201562242489P 2015-10-16 2015-10-16
US201562255635P 2015-11-16 2015-11-16
PCT/US2016/023524 WO2016154177A2 (en) 2015-03-23 2016-03-22 Antibodies to icos

Publications (1)

Publication Number Publication Date
CY1123409T1 true CY1123409T1 (el) 2021-12-31

Family

ID=56978549

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100755T CY1123409T1 (el) 2015-03-23 2020-08-12 Αντισωματα κατα toy icos (επαγωγιμος συνδιεγερτης τ-κυτταρων)

Country Status (34)

Country Link
US (3) US10023635B2 (el)
EP (2) EP3273992B1 (el)
JP (2) JP6944924B2 (el)
KR (2) KR20230164243A (el)
CN (2) CN107530428B (el)
AU (2) AU2016235362B2 (el)
BR (1) BR112017020054A2 (el)
CA (1) CA2978185A1 (el)
CL (1) CL2017002401A1 (el)
CO (1) CO2017010618A2 (el)
CY (1) CY1123409T1 (el)
DK (1) DK3273992T3 (el)
EA (1) EA037621B1 (el)
EC (1) ECSP17070399A (el)
ES (1) ES2811345T3 (el)
HK (1) HK1248127A1 (el)
HR (1) HRP20201090T1 (el)
HU (1) HUE049938T2 (el)
IL (2) IL254338B (el)
LT (1) LT3273992T (el)
MA (1) MA53297A (el)
MD (1) MD3273992T2 (el)
ME (1) ME03819B (el)
MX (2) MX2017012129A (el)
PH (1) PH12017501748A1 (el)
PL (1) PL3273992T3 (el)
PT (1) PT3273992T (el)
RS (1) RS60614B1 (el)
RU (1) RU2742241C2 (el)
SG (2) SG10202001019TA (el)
SI (1) SI3273992T1 (el)
TW (1) TWI719970B (el)
WO (1) WO2016154177A2 (el)
ZA (1) ZA201705920B (el)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3375791A1 (en) 2009-09-30 2018-09-19 Memorial Sloan Kettering Cancer Center Combination immunotherapy for the treatment of cancer
EP2691419B1 (en) 2011-03-31 2016-11-09 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies directed against icos and uses thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN113456812A (zh) 2015-01-09 2021-10-01 埃图比克斯公司 用于联合免疫治疗的方法和组合物
PL3273992T3 (pl) * 2015-03-23 2020-11-16 Jounce Therapeutics, Inc. Przeciwciała przeciwko icos
EP3286213B1 (en) * 2015-04-20 2021-08-04 Etubics Corporation Methods and compositions for combination immunotherapy
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
TW201723190A (zh) 2015-10-22 2017-07-01 永斯醫療股份有限公司 用於測定icos表現之基因印記
EP3440076B1 (en) 2016-04-07 2022-06-01 GlaxoSmithKline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
EA201892128A1 (ru) 2016-04-07 2019-04-30 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Гетероциклические амиды, полезные в качестве модуляторов
CN109475603B (zh) 2016-06-20 2023-06-13 科马布有限公司 抗pd-l1抗体
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
TWI760352B (zh) * 2016-08-09 2022-04-11 英商克馬伯有限公司 抗ｉｃｏｓ抗體
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP7290568B2 (ja) * 2016-12-20 2023-06-13 カイマブ・リミテッド 癌免疫療法のための併用療法での多重特異性抗体
WO2018115859A1 (en) * 2016-12-20 2018-06-28 Kymab Limited Multispecific antibody with combination therapy for immuno-oncology
WO2018154520A1 (en) 2017-02-27 2018-08-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
WO2018187191A1 (en) * 2017-04-03 2018-10-11 Jounce Therapeutics, Inc Compositions and methods for the treatment of cancer
TWI788340B (zh) * 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
CN110831971A (zh) 2017-06-09 2020-02-21 葛兰素史克知识产权开发有限公司 用icos激动剂和ox40激动剂治疗癌症的组合疗法
CN110709423A (zh) 2017-06-09 2020-01-17 葛兰素史克知识产权开发有限公司 用icos激动剂和ox40激动剂治疗癌症的组合疗法
BR112019025325A2 (pt) 2017-06-09 2020-06-23 Glaxosmithkline Intellectual Property Development Limited Métodos para tratar câncer, para fabricar um anticorpo anti-icos ou porção de ligação a antígeno do mesmo, para fabricar um anticorpo anti-pd1 ou porção de ligação a antígeno do mesmo, para fabricar um anticorpo anti-pdl1 ou porção de ligação a antígeno do mesmo, anticorpo anti-icos ou fragmento de ligação a antígeno do mesmo e um anticorpo anti-pd1 ou fragmento de ligação a antígeno do mesmo, anticorpo anti-icos ou fragmento de ligação a antígeno do mesmo e um anticorpo anti-pd-l1 ou fragmento de ligação a antígeno do mesmo, uso de um anticorpo anti-icos ou porção de ligação a antígeno do mesmo e um anticorpo anti-pd1 ou porção de ligação a antígeno do mesmo, polinucleotídeo, vetor, e, célula hospedeira
US11299540B2 (en) 2017-06-18 2022-04-12 Kindred Biosciences, Inc. IL17A antibodies and antagonists for veterinary use
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2019005762A1 (en) * 2017-06-26 2019-01-03 Abbvie Inc. TREATMENT OF NON-SMALL CELL LUNG CANCER
GB201712032D0 (en) 2017-07-26 2017-09-06 Bioinvent Int Ab Antibodies and uses thereof
CA3070297A1 (en) * 2017-08-11 2019-02-14 Genentech, Inc. Anti-cd8 antibodies and uses thereof
EP3692066A2 (en) 2017-09-14 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Combination treatment for cancer
EP3684949B1 (en) * 2017-09-22 2024-04-17 University of Washington In situ combinatorial labeling of cellular molecules
TW201927771A (zh) 2017-10-05 2019-07-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 可作為蛋白質調節劑之雜環醯胺及其使用方法
US11377440B2 (en) 2017-10-05 2022-07-05 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING)
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3728314A1 (en) * 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
JP7391868B2 (ja) 2017-12-22 2023-12-05 ジョウンセ セラピューティクス， インク． Ｌｉｌｒｂ２に対する抗体
TW202000891A (zh) 2018-03-07 2020-01-01 英商葛蘭素史克智慧財產發展有限公司 純化抗體之方法
AU2019236865A1 (en) 2018-03-23 2020-10-01 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
JP2021523213A (ja) * 2018-05-14 2021-09-02 ジャウンス セラピューティックス， インク．Ｊｏｕｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 癌を治療する方法
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
WO2019229613A1 (en) 2018-05-31 2019-12-05 Glaxosmithkline Intellectual Property Development Limited Combined therapy with icos binding proteins and argininemethyltransferase inhibitors
BR112020023451A2 (pt) 2018-05-31 2021-02-23 Glaxosmithkline Intellectual Property Development Limited terapia combinada
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
WO2020031087A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
US20210353750A1 (en) * 2018-10-18 2021-11-18 Jounce Therapeutics, Inc. Methods of Treating Cancer
BR112021007082A2 (pt) 2018-10-22 2021-08-03 Glaxosmithkline Intellectual Property Development Limited dosagem
EP3870610A1 (en) 2018-10-24 2021-09-01 Jounce Therapeutics, Inc. Methods and compositions for the treatment of cancer and infectious diseases
US20210355222A1 (en) 2018-10-26 2021-11-18 Jounce Therapeutics, Inc. Methods of Treating Cancer
US20220135682A1 (en) 2019-03-11 2022-05-05 Jounce Therapeutics, Inc. Anti-ICOS Antibodies for the Treatment of Cancer
CN114302875A (zh) 2019-05-16 2022-04-08 斯汀塞拉股份有限公司 氧代吖啶基乙酸衍生物及使用方法
JP2022533194A (ja) 2019-05-16 2022-07-21 スティングセラ インコーポレイテッド ベンゾ［ｂ］［１，８］ナフチリジン酢酸誘導体および使用方法
CN114174538A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 适合于免疫肿瘤学疗法的多肿瘤基因特征
US20220233691A1 (en) 2019-05-30 2022-07-28 Bristol-Myers Squibb Company Cell localization signature and combination therapy
EP3976832A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
WO2021018941A1 (en) 2019-07-31 2021-02-04 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
WO2021046289A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and ipilimumab
US11878009B2 (en) 2019-09-10 2024-01-23 Great Novel Therapeutics Biotech & Medicals Corporation Anticancer combination of chidamide and celecoxib salts
US20220389106A1 (en) * 2019-09-20 2022-12-08 Board Of Regents, The University Of Texas System Anti-epha10 antibodies and methods of use thereof
US20220378909A1 (en) 2019-11-05 2022-12-01 Jounce Therapeutics, Inc. Methods of Treating Cancer with Anti-PD-1 Antibodies
MX2022008412A (es) 2020-01-07 2022-08-08 Univ Texas Variantes de enzima que agotan metiltioadenosina/adenosina mejorada humana para terapia de cancer.
EP4090771A1 (en) 2020-01-13 2022-11-23 Jounce Therapeutics, Inc. Methods for the treatment of cancer
WO2021209357A1 (en) 2020-04-14 2021-10-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
CA3171597A1 (en) 2020-04-14 2021-10-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
US20230149543A1 (en) 2020-04-14 2023-05-18 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer based upon an icos antbody and a pd-l1 antibody tgf-bets-receptor fusion protein
IL297313A (en) 2020-04-20 2022-12-01 Jounce Therapeutics Inc Compositions and methods for vaccination and treatment of infectious diseases
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
MX2023002326A (es) 2020-08-31 2023-03-21 Bristol Myers Squibb Co Firma de localizacion celular e inmunoterapia.
US20230398150A1 (en) * 2020-10-16 2023-12-14 Fred Hutchinson Cancer Center Specific targeting of tumor-infiltrating regulatory t cells (tregs) using icos and il-1r
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
EP4267172A1 (en) 2020-12-28 2023-11-01 Bristol-Myers Squibb Company Subcutaneous administration of pd1/pd-l1 antibodies
WO2022146947A1 (en) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
AU2022218137A1 (en) 2021-02-03 2023-08-24 Mozart Therapeutics, Inc. Binding agents and methods of using the same
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
CA3219336A1 (en) * 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023222854A1 (en) 2022-05-18 2023-11-23 Kymab Limited Uses of anti-icos antibodies
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
DE69830315T2 (de) 1997-06-24 2006-02-02 Genentech Inc., San Francisco Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
DE19821060A1 (de) 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
DE59813875D1 (de) 1997-09-23 2007-02-22 Bundesrepublik Deutschland Let Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
ES2340112T3 (es) 1998-04-20 2010-05-28 Glycart Biotechnology Ag Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos.
ATE397457T1 (de) 1998-12-03 2008-06-15 Univ California Stimulierung von t-zellen gegen selbstantigene unter verwendung von ctla-4 inhibierenden wirkstoffen
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
SI1149114T1 (sl) 1999-02-03 2014-08-29 Amgen Inc. Polipeptidi, vkljuäśeni v imunskem odgovoru
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
CA2589418A1 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US6521749B1 (en) 1999-09-21 2003-02-18 Genetics Institute, Inc. GL50 nucleic acids and uses therefor
JP4668498B2 (ja) 1999-10-19 2011-04-13 協和発酵キリン株式会社 ポリペプチドの製造方法
WO2001044463A1 (en) 1999-12-15 2001-06-21 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
JP3597140B2 (ja) * 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
EP1320599A2 (en) 2000-06-28 2003-06-25 Genetics Institute, LLC Pd-l2 molecules: pd-1 ligands and uses therefor
PL218428B1 (pl) 2000-10-06 2014-12-31 Kyowa Hakko Kogyo Kk Komórka, sposoby wytwarzania przeciwciał, leki zawierające przeciwciała, komórka CHO i przeciwciało klasy IgG
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7041870B2 (en) 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US20030124149A1 (en) 2001-07-06 2003-07-03 Shalaby Shalaby W. Bioactive absorbable microparticles as therapeutic vaccines
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
WO2003035835A2 (en) 2001-10-25 2003-05-01 Genentech, Inc. Glycoprotein compositions
CA2466698A1 (en) 2001-11-09 2003-05-15 Medigene Aktiengesellschaft Cellular vaccines comprising adjuvants
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
ES2362419T3 (es) 2002-04-09 2011-07-05 Kyowa Hakko Kirin Co., Ltd. Células con depresión o deleción de la actividad de la proteína que participa en el transporte de gdp-fucosa.
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
WO2003084569A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition anticorps
AU2003239966B9 (en) 2002-06-03 2010-08-26 Genentech, Inc. Synthetic antibody phage libraries
DK2206517T3 (da) 2002-07-03 2023-11-06 Ono Pharmaceutical Co Immunpotentierende sammensætninger omfattende af anti-PD-L1-antistoffer
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AR042485A1 (es) 2002-12-16 2005-06-22 Genentech Inc Anticuerpo humanizado que se une al cd20 humano
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
CA2510003A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
AU2004280065A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
US8268582B2 (en) 2003-10-22 2012-09-18 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
EA036531B1 (ru) 2003-11-05 2020-11-19 Роше Гликарт Аг Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
ZA200608130B (en) 2004-03-31 2008-12-31 Genentech Inc Humanized anti-TGF-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
ES2442386T3 (es) * 2004-04-23 2014-02-11 Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr Método para el tratamiento de condiciones mediadas por células T por la disminución de las células positivas de ICOS in vivo.
AU2005259958A1 (en) 2004-06-29 2006-01-12 The Johns Hopkins University Amelioration of drug-induced toxicity
EP1841874B1 (en) 2005-01-27 2010-01-06 Five Prime Therapeutics, Inc. Leader sequences for directing secretion of polypeptides and methods for production thereof
JP2006265155A (ja) 2005-03-23 2006-10-05 Link Genomics Kk 癌の免疫療法
EP3130350A1 (en) 2005-06-08 2017-02-15 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
US8679490B2 (en) 2005-11-07 2014-03-25 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008090959A1 (ja) 2007-01-24 2008-07-31 Kyowa Hakko Kirin Co., Ltd. エフェクター活性が増強された遺伝子組換え抗体組成物
EP2703011A3 (en) * 2007-05-07 2014-03-26 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
EP3381937A3 (en) * 2009-08-13 2018-10-31 The Johns Hopkins University Methods of modulating immune function
EP3375791A1 (en) 2009-09-30 2018-09-19 Memorial Sloan Kettering Cancer Center Combination immunotherapy for the treatment of cancer
KR101853702B1 (ko) 2009-12-07 2018-05-03 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 항-종양 항체 치료를 향상시키는 방법
AU2011212794B2 (en) * 2010-02-04 2014-06-26 The Trustees Of The University Of Pennsylvania ICOS critically regulates the expansion and function of inflammatory human Th17 cells
US9410205B2 (en) 2010-02-18 2016-08-09 New York University Methods for predicting survival in metastatic melanoma patients
EP2677869B1 (en) * 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP2691419B1 (en) * 2011-03-31 2016-11-09 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies directed against icos and uses thereof
ES2648176T3 (es) 2012-07-12 2017-12-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos de predicción del tiempo de supervivencia y de la respuesta al tratamiento de un paciente que padece un cáncer sólido con un distintivo de al menos 7 genes
WO2014066834A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
BR112015023120A2 (pt) 2013-03-15 2017-11-21 Genentech Inc método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
WO2014150646A1 (en) 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Ido inhibitors
MA41414A (fr) * 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
PL3273992T3 (pl) * 2015-03-23 2020-11-16 Jounce Therapeutics, Inc. Przeciwciała przeciwko icos
TW201723190A (zh) * 2015-10-22 2017-07-01 永斯醫療股份有限公司 用於測定icos表現之基因印記
CN109310763B (zh) * 2016-06-10 2022-10-21 Io治疗公司 用于癌症免疫疗法的受体选择性类视黄醇和rexinoid化合物和免疫调节剂
US9567399B1 (en) * 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines

Also Published As

Publication number Publication date
AU2022201408A1 (en) 2022-03-24
EA201792078A1 (ru) 2018-02-28
PT3273992T (pt) 2020-08-21
TWI719970B (zh) 2021-03-01
ES2811345T3 (es) 2021-03-11
ECSP17070399A (es) 2018-02-28
DK3273992T3 (da) 2020-07-27
JP2018512170A (ja) 2018-05-17
US20210171635A1 (en) 2021-06-10
BR112017020054A2 (pt) 2018-06-05
ME03819B (me) 2021-04-20
SG11201707769VA (en) 2017-10-30
CL2017002401A1 (es) 2018-03-16
RU2017137020A (ru) 2019-04-23
HK1248127A1 (zh) 2018-10-12
AU2016235362B2 (en) 2021-12-16
RS60614B1 (sr) 2020-08-31
RU2742241C2 (ru) 2021-02-04
IL286807A (en) 2021-10-31
MA53297A (fr) 2022-05-04
TW201639884A (zh) 2016-11-16
PL3273992T3 (pl) 2020-11-16
CA2978185A1 (en) 2016-09-29
WO2016154177A3 (en) 2017-02-02
US10570203B2 (en) 2020-02-25
JP6944924B2 (ja) 2021-10-06
WO2016154177A2 (en) 2016-09-29
RU2017137020A3 (el) 2019-09-03
ZA201705920B (en) 2019-11-27
MD3273992T2 (ro) 2020-08-31
HUE049938T2 (hu) 2020-11-30
CO2017010618A2 (es) 2018-03-09
US20160304610A1 (en) 2016-10-20
KR20230164243A (ko) 2023-12-01
SI3273992T1 (sl) 2020-09-30
PH12017501748A1 (en) 2018-04-11
CN107530428B (zh) 2022-05-13
EP3273992B1 (en) 2020-05-13
KR20170129902A (ko) 2017-11-27
IL254338A0 (en) 2017-11-30
EP3273992A4 (en) 2018-05-02
SG10202001019TA (en) 2020-04-29
EP3735986A1 (en) 2020-11-11
CN107530428A (zh) 2018-01-02
US10023635B2 (en) 2018-07-17
LT3273992T (lt) 2020-10-26
EP3273992A2 (en) 2018-01-31
US20180355041A1 (en) 2018-12-13
MX2021011667A (es) 2021-10-22
JP2022002520A (ja) 2022-01-11
AU2016235362A1 (en) 2017-09-21
HRP20201090T1 (hr) 2020-10-30
CN114907481A (zh) 2022-08-16
MX2017012129A (es) 2018-06-15
EA037621B1 (ru) 2021-04-22
IL254338B (en) 2021-10-31

Similar Documents

Publication Publication Date Title
CY1123409T1 (el) Αντισωματα κατα toy icos (επαγωγιμος συνδιεγερτης τ-κυτταρων)
CY1124730T1 (el) Αντισωματα εναντι pd-1 και χρησεις αυτων
CY1123957T1 (el) Θεραπεια συνδυασμου για καρκινο
CY1123220T1 (el) Πρωτεϊνες συνδεσης anti-lag-3
CY1124299T1 (el) Συνδυαστικες θεραπειες που περιλαμβανουν μορια αντισωματων κατα toy lag-3
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
EA202091540A1 (ru) Антитела к lilrb2
CL2019000424A1 (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
CY1122478T1 (el) Συνθεσεις που περιεχουν anti-cd38 αντισωματα και λεναλιδομιδη
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MY186016A (en) Anti-tigit antibodies and methods of use
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
PH12016501763A1 (en) Multispecific antibodies
EA202092435A2 (ru) Моноклональные антитела против bcma
NI201700037A (es) Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos
EA201792443A1 (ru) МОДУЛЯТОРЫ K-Ras
DK3795177T3 (da) Claudin-18.2-specifikke immunoreceptorer og t-celleepitoper
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
CL2017002596A1 (es) Neutralización del virus chikungunya mediada por anticuerpos
EA201992756A2 (ru) Антитела против cd48 и их конъюгаты
MX2018000715A (es) Metodos para tratar cancer usando apilimod.